Bordeaux

• Efficacy and Safety of Methotrexate versus Placebo in Adults with Atopic Dermatitis Ended recruitment
  2023-504443-13-00 5 2024-01-29 moderate to severe atopic dermatitis
• Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended recruitment
  2023-503428-24-00 4 2024-01-19 Neoplasms, Head and Neck
• DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small … Ended recruitment
  2023-506008-20-00 3 2024-01-11 Extensive-stage small cell lung carcinoma (ES-SCLC)
• A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB … Ended recruitment
  2023-506139-13-00 5 2024-01-04 Treatment naïve patients with MF
• Immune response to the recombinant Zoster Vaccine in people living with HIV over 50 years of age compared to non-HIV age- and gender-matched … Ended recruitment
  2023-504482-23-00 4 2023-12-14 Human Immunodeficiency Virus (HIV)
• Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M … Ended recruitment
  2022-502975-45-00 5 2023-12-12 Metastatic leiomyosarcoma
• Phase I study evaluating the safety and efficacy of MEDI5752 in combination with stereotactic radiotherapy in patients with metastatic sarco … Ended recruitment
  2024-515551-38-00 3 2023-12-12 Metastatic soft tissue sarcoma
• Determine effectiveness of Anifrolumab In Systemic sclerosis Ended recruitment
  2023-505976-31-00 5 2023-11-24 Systemic Sclerosis (SSc) presenting with Limited or Diffuse Cutaneous
• A Study of an Intermittent ADT Approach with Apalutamide Monotherapy in Participants with mCSPC Ended recruitment
  2022-502686-24-00 5 2023-11-22 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• A Phase 3, Open-label, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Chi … Ended recruitment
  2023-503294-37-00 5 2023-11-20 Osteogenesis Imperfecta
• Trial of efficacy and safety of MC0518 versus best available therapy in patients with steroid-refractory acute graft versus host disease Ended recruitment
  2023-503952-28-00 4 2023-11-13 Steroid refractory Acute Graft versus host Disease
• A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N … Ended recruitment
  2022-500802-16-00 5 2023-11-01 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung
• A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’ … Ended recruitment
  2022-502966-26-01 5 2023-10-27 Sjögren’s syndrome
• Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants with Multiple System Atrophy Ended recruitment
  2023-504876-12-00 5 2023-10-25 Neurogenic Orthostatic Hypotension
• A Phase 1/2 Study of BMS-986449 with and without Nivolumab in Participants with Solid Tumors Ended recruitment
  2023-503484-42-00 7 2023-10-19 Advanced, metastatic, solid malignancy
• A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD … Ended recruitment
  2022-501343-33-00 5 2023-10-18 Biochemically recurrent prostate cancer
• Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma Ended recruitment
  2023-503652-27-00 5 2023-10-06 Melanoma
• ELVN-002 in Solid Tumors with a HER2 Genetic Alteration Ended recruitment
  2022-502695-23-00 1 2023-09-27 Phase 1a Monotherapy Dose Escalation and Exploration: HER2 mutant, HE
• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received … Ended recruitment
  2022-502593-17-00 5 2023-09-19 Locally advanced or metastatic hormone receptor (HR)-positive, human e
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• SUrGery with or without dARolutamide in high-risk and/or locally advanced prostate cancer Ended recruitment
  2022-501518-67-00 4 2023-08-10 High-risk and/or locally advanced prostate cancer
• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended recruitment
  2022-501176-26-00 5 2023-08-04 Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com … Ended recruitment
  2022-501576-25-00 5 2023-07-07 Melanoma

Showing 649–672 of 1,096 trials